GE HealthCare Technologies Inc. (GEHC)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $bn | 17 | 18 | 18 | 20 | 20 | 21 | 20 | 22 |
| Operating profit | $bn | 3 | 3 | ||||||
| Net profit | $bn | 14 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| EPS reported | $ | 4.55 | 3.45 | ||||||
| Operating cashflow per share | $ | 4.35 | 3.13 | ||||||
| Capex per share | $ | 1.06 | 1.15 | ||||||
| FCF per share | $ | 3.30 | 1.98 | ||||||
| Free cash flow | $bn | 2 | 1 | ||||||
| Net debt | $bn | 5 | 8 | ||||||
| Book value equity | $bn | 10 | 11 | ||||||
| Book value per share | $ | 22.55 | 24.17 | ||||||
| Number of shares | m | 460.27 | 454 | ||||||
| DPS (TTM paid) | $ | 0.14 | 0.18 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 18.03 | 19.31 | ||||||
| P/B LTM | x | 3.61 | 3.41 | ||||||
| P/S LTM | x | 1.82 | 1.85 | ||||||
| P/FCF LTM | x | 24.86 | 41.84 | ||||||
| EV/EBITDA LTM | x | 11.34 | 12.36 | ||||||
| EV/Sales LTM | x | 2.08 | 2.04 | ||||||
| Earnings Yield LTM | % | +5.55% | +5.18% | ||||||
| FCF Yield | % | +4.02% | +2.39% | ||||||
| Quality | |||||||||
| ROE | % | +20.08% | +15.16% | ||||||
| ROIC | % | +8.84% | +8.15% | ||||||
| Operating margin | % | +13.39% | +12.70% | ||||||
| Gross margin | % | +39.99% | +42.90% | ||||||
| FCF/Sales | % | +7.30% | +4.42% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +4.84% | -20.51% | ||||||
| Sales Growth YoY | % | +4.84% | +2.90% | ||||||
| Net Income Growth YoY | % | +4.57% | -20.12% | ||||||
| FCF Growth | % | -2.84% | -42.26% | ||||||
| Operating Profit Growth | % | +5.22% | -2.06% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | +0.17% | +0.19% | ||||||
| Dividend Growth | % | +16.67% | +50.00% | ||||||
| Payout Ratio | % | +3.06% | +4.06% | ||||||
| FCF/Debt | x | 0.15 | 0.09 | ||||||
| Net Debt/EBITDA | x | 1.45 | 2.30 | ||||||
| EBIT/Net interest | x | 6.14 | 5.90 | ||||||
| Net debt/market cap | % | +26.71% | +30.32% | ||||||
| Net debt/Equity | x | 0.53 | 0.73 | ||||||
| Gross debt/equity | x | 0.96 | 0.92 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
GE HealthCare Technologies Inc. is a global medical technology company that creates, manufactures, and markets a diverse range of medical devices, services, and integrated digital solutions. These offerings are designed to assist in the diagnosis, treatment, and ongoing monitoring of patients. The company boasts an extensive international presence, serving markets across the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, and Hong Kong, among other regions. Its operations are structured across four primary business divisions: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging division specializes in advanced diagnostic imaging technologies, including systems for molecular imaging, Computed Tomography (CT) scans, Magnetic Resonance (MR) imaging, image-guided therapy, and X-ray, alongside specialized women's health products. The Ultrasound segment delivers a comprehensive suite of ultrasound solutions utilized for the screening, diagnosis, treatment, and monitoring of various diseases. These applications span radiology, primary care, women's health, cardiovascular diagnostics, point-of-care, and portable handheld devices, in addition to products supporting surgical visualization and guidance. The Patient Care Solutions segment is dedicated to providing essential medical devices, consumable products, services, and digital platforms. Its portfolio encompasses patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal-infant care products. The Pharmaceutical Diagnostics segment supplies specialized diagnostic agents to the radiology and nuclear medicine industries. These include contrast media pharmaceuticals, administered to patients prior to scans like CT, angiography, X-ray, and MR, to enhance the visibility of internal tissues and structures. It also offers molecular imaging agents, or radiopharmaceuticals – molecular tracers labeled with radioisotopes – injected into patients for advanced diagnostic imaging applications such as Single-Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), and specific ultrasound procedures. Established in 2022, GE HealthCare Technologies Inc. maintains its corporate headquarters in Chicago, Illinois.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
GE HealthCare Technologies Inc. (GEHC)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
GE HealthCare Technologies Inc. is a global medical technology company that creates, manufactures, and markets a diverse range of medical devices, services, and integrated digital solutions. These offerings are designed to assist in the diagnosis, treatment, and ongoing monitoring of patients. The company boasts an extensive international presence, serving markets across the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, and Hong Kong, among other regions. Its operations are structured across four primary business divisions: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging division specializes in advanced diagnostic imaging technologies, including systems for molecular imaging, Computed Tomography (CT) scans, Magnetic Resonance (MR) imaging, image-guided therapy, and X-ray, alongside specialized women's health products. The Ultrasound segment delivers a comprehensive suite of ultrasound solutions utilized for the screening, diagnosis, treatment, and monitoring of various diseases. These applications span radiology, primary care, women's health, cardiovascular diagnostics, point-of-care, and portable handheld devices, in addition to products supporting surgical visualization and guidance. The Patient Care Solutions segment is dedicated to providing essential medical devices, consumable products, services, and digital platforms. Its portfolio encompasses patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal-infant care products. The Pharmaceutical Diagnostics segment supplies specialized diagnostic agents to the radiology and nuclear medicine industries. These include contrast media pharmaceuticals, administered to patients prior to scans like CT, angiography, X-ray, and MR, to enhance the visibility of internal tissues and structures. It also offers molecular imaging agents, or radiopharmaceuticals – molecular tracers labeled with radioisotopes – injected into patients for advanced diagnostic imaging applications such as Single-Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), and specific ultrasound procedures. Established in 2022, GE HealthCare Technologies Inc. maintains its corporate headquarters in Chicago, Illinois.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free